

# Yuan Chen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/824423/publications.pdf>

Version: 2024-02-01

58  
papers

2,054  
citations

394421

19  
h-index

254184

43  
g-index

60  
all docs

60  
docs citations

60  
times ranked

3572  
citing authors

#	ARTICLE	IF	CITATIONS
1	The CXCL8-CXCR1/2 pathways in cancer. <i>Cytokine and Growth Factor Reviews</i> , 2016, 31, 61-71.	7.2	471
2	Notch signaling and EMT in non-small cell lung cancer: biological significance and therapeutic application. <i>Journal of Hematology and Oncology</i> , 2014, 7, 87.	17.0	196
3	Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 1154-1164.	10.7	107
4	Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2020, 8, 45-53.	10.7	105
5	Meta-analysis reveals the correlation of Notch signaling with non-small cell lung cancer progression and prognosis. <i>Scientific Reports</i> , 2015, 5, 10338.	3.3	96
6	Estrogen receptor $\beta$ promotes the vasculogenic mimicry (VM) and cell invasion via altering the lncRNA-MALAT1/miR-145-5p/NEDD9 signals in lung cancer. <i>Oncogene</i> , 2019, 38, 1225-1238.	5.9	89
7	Efficacy and Biomarker Analysis of Camrelizumab in Combination with Apatinib in Patients with Advanced Nonsquamous NSCLC Previously Treated with Chemotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1296-1304.	7.0	79
8	Expression of Notch1 Correlates with Breast Cancer Progression and Prognosis. <i>PLoS ONE</i> , 2015, 10, e0131689.	2.5	75
9	Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ER $\beta$ /CCL2/CCR2 EMT/MMP9 signals. <i>Oncotarget</i> , 2016, 7, 7842-7855.	1.8	72
10	Circulating tumor DNA clearance predicts prognosis across treatment regimen in a large real-world longitudinally monitored advanced non-small cell lung cancer cohort. <i>Translational Lung Cancer Research</i> , 2020, 9, 269-279.	2.8	64
11	Cancer associated fibroblasts-derived exosomes contribute to radioresistance through promoting colorectal cancer stem cells phenotype. <i>Experimental Cell Research</i> , 2020, 391, 111956.	2.6	61
12	Emerging roles of Nrf2 signal in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 14.	17.0	50
13	Phase II study of savolitinib in patients (pts) with pulmonary sarcomatoid carcinoma (PSC) and other types of non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutations (METex14+). <i>Journal of Clinical Oncology</i> , 2020, 38, 9519-9519.	1.6	50
14	Modification of platinum sensitivity by KEAP1/NRF2 signals in non-small cell lung cancer. <i>Journal of Hematology and Oncology</i> , 2016, 9, 83.	17.0	45
15	DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling. <i>Oncotarget</i> , 2015, 6, 5877-5888.	1.8	40
16	Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. <i>Oncotarget</i> , 2015, 6, 31203-31215.	1.8	37
17	EGFR T790M ctDNA testing platforms and their role as companion diagnostics: Correlation with clinical outcomes to EGFR-TKIs. <i>Cancer Letters</i> , 2017, 403, 186-194.	7.2	27
18	A nomogram for predicting mortality in patients with COVID-19 and solid tumors: a multicenter retrospective cohort study. , 2020, 8, e001314.		26

#	ARTICLE	IF	CITATIONS
19	Flightless I Homolog Represses Prostate Cancer Progression through Targeting Androgen Receptor Signaling. <i>Clinical Cancer Research</i> , 2016, 22, 1531-1544.	7.0	24
20	Decoding the Evolutionary Response to Ensartinib in Patients With ALK-Positive NSCLC by Dynamic Circulating Tumor DNA Sequencing. <i>Journal of Thoracic Oncology</i> , 2021, 16, 827-839.	1.1	24
21	The roles of CC chemokines in response to radiation. <i>Radiation Oncology</i> , 2022, 17, 63.	2.7	21
22	The relationship between UGT1A1 gene polymorphism and irinotecan effect on extensive-stage small-cell lung cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 3575.	2.0	20
23	In Vitro Evaluation of the Inhibitory Potential of Pharmaceutical Excipients on Human Carboxylesterase 1A and 2. <i>PLoS ONE</i> , 2014, 9, e93819.	2.5	18
24	PDPN is a prognostic biomarker and correlated with immune infiltrating in gastric cancer. <i>Medicine (United States)</i> , 2020, 99, e19957.	1.0	17
25	The Experiences of Community-dwelling older adults during the COVID-19 Lockdown in Wuhan: A qualitative study. <i>Journal of Advanced Nursing</i> , 2021, 77, 4805-4814.	3.3	17
26	Parallel serial assessment of somatic mutation and methylation profile from circulating tumor DNA predicts treatment response and impending disease progression in osimertinib-treated lung adenocarcinoma patients. <i>Translational Lung Cancer Research</i> , 2019, 8, 1016-1028.	2.8	16
27	Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small cell lung cancer: A multicenter, randomized, double-blind, phase III trial. <i>Cancer Communications</i> , 2021, 41, 889-903.	9.2	16
28	Association of single nucleotide polymorphisms of ABCB1, OPRM1 and COMT with pain perception in cancer patients. <i>Journal of Huazhong University of Science and Technology [Medical Sciences]</i> , 2015, 35, 752-758.	1.0	14
29	mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition. <i>Acta Pharmacologica Sinica</i> , 2019, 40, 1085-1094.	6.1	14
30	Nedaplatin Plus Docetaxel Versus Cisplatin Plus Docetaxel as First-Line Chemotherapy for Advanced Squamous Cell Carcinoma of the Lung – A Multicenter, Open-label, Randomized, Phase III Trial. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1743-1749.	1.1	13
31	A Phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer – The FALUCA study. <i>Lung Cancer</i> , 2020, 146, 252-262.	2.0	12
32	Biomarkers and Future Perspectives for Hepatocellular Carcinoma Immunotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 716844.	2.8	12
33	Retrospective study of irinotecan/cisplatin followed by etoposide/cisplatin or the reverse sequence in extensive-stage small cell lung cancer. <i>OncoTargets and Therapy</i> , 2015, 8, 2209.	2.0	11
34	Prior Study of Cross-Cultural Validation of McGill Quality-of-Life Questionnaire in Mainland Mandarin Chinese Patients With Cancer. <i>American Journal of Hospice and Palliative Medicine</i> , 2015, 32, 709-714.	1.4	10
35	Irinotecan-platinum combination therapy for previously untreated extensive-stage small cell lung cancer patients: a meta-analysis. <i>BMC Cancer</i> , 2018, 18, 808.	2.6	10
36	Comparison of the oncological, perioperative and functional outcomes of partial nephrectomy versus radical nephrectomy for clinical T1b renal cell carcinoma: A systematic review and meta-analysis of retrospective studies. <i>Asian Journal of Urology</i> , 2021, 8, 117-125.	1.2	10

#	ARTICLE	IF	CITATIONS
37	Characteristics of immune and inflammatory responses among different age groups of pediatric patients with COVID-19 in China. <i>World Journal of Pediatrics</i> , 2021, 17, 375-384.	1.8	10
38	The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin. <i>Supportive Care in Cancer</i> , 2018, 26, 2763-2767.	2.2	9
39	An online tool for predicting the prognosis of cancer patients with SARS-CoV-2 infection: a multi-center study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 1247-1257.	2.5	8
40	A consensus on immunotherapy from the 2017 Chinese Lung Cancer Summit expert panel. <i>Translational Lung Cancer Research</i> , 2018, 7, 428-436.	2.8	7
41	SIX1 Predicts Poor Prognosis and Facilitates the Progression of Non-small Lung Cancer via Activating the Notch Signaling Pathway. <i>Journal of Cancer</i> , 2022, 13, 527-540.	2.5	7
42	miR-34C Disrupts the Stemness of Purified CD133 + Prostatic Cancer Stem Cells. <i>Urology</i> , 2016, 96, 177.e1-177.e9.	1.0	6
43	Impact of marital status on survival in patients with stage 1A NSCLC. <i>Aging</i> , 2022, 14, 770-779.	3.1	6
44	Discussion of Advance Care Planning on end of life decisions with lung cancer patients in Wuhan China: Attitude, Timing, and Future Directions. <i>Internal Medicine Journal</i> , 2020, . .	0.8	5
45	Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers. <i>Oncotarget</i> , 2017, 8, 62330-62338.	1.8	5
46	Abstract CT158: ctDNA analysis in the savolitinib phase II study in Non-Small Cell Lung Cancer (NSCLC) patients (pts) harboring <i>MET</i> exon 14 skipping alterations ( <i>MET</i> ex14). <i>Cancer Research</i> , 2021, 81, CT158-CT158.	0.9	4
47	Knowledge, Practices, and Perceived Barriers in Cancer Pain Management at Oncology Units: A Cross-Sectional Survey of Medical Staff in China. <i>Journal of Pain Research</i> , 2022, Volume 15, 159-169.	2.0	4
48	Long noncoding RNA PVT1 regulates the proliferation and apoptosis of ARPE-19 cells <i>in vitro</i> via the miR-1301-3p/KLF7 axis. <i>Cell Cycle</i> , 2022, 21, 1590-1598.	2.6	4
49	Sitagliptin Alleviates Radiation-Induced Intestinal Injury by Activating NRF2-Antioxidant Axis, Mitigating NLRP3 Inf-lammasome Activation, and Reversing Gut Microbiota Disorder. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-17.	4.0	3
50	CYFRA 21-1 as an early predictor of first line chemotherapy response in advanced non small cell lung cancer. <i>Chinese-German Journal of Clinical Oncology</i> , 2007, 6, P250-P253.	0.1	1
51	Preliminary results of gentamycin combined with sodium bicarbonate for prevention of irinotecan-induced diarrhea. <i>Frontiers of Medicine in China</i> , 2009, 3, 470-474.	0.1	1
52	Leinal polypeptide promotes NK cells to suppress PCa survival <i>in vitro</i> . <i>Oncology Letters</i> , 2018, 16, 425-430.	1.8	1
53	Lower lobe origin is related to unfavorable outcomes in patients with stage III lung cancer treated with radical chemoradiotherapy. <i>Tumori</i> , 2021, 107, 400-406.	1.1	1
54	Identification of osimertinib resistance mechanisms in Chinese NSCLC patients: Analysis from AURA17 trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 9077-9077.	1.6	1

#	ARTICLE	IF	CITATIONS
55	Treatment beyond progression with chemo-immunotherapy in an advanced esophageal squamous cell carcinoma patient: a case report. <i>Translational Cancer Research</i> , 2021, 10, 4973-4978.	1.0	1
56	Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9114-9114.	1.6	1
57	Detect T790M in cell free tumor DNA of Chinese advanced non-small cell lung cancer adenocarcinoma patients by different platforms and evaluate clinical outcomes of T790M positive patients with osimertinib monotherapy.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9104-TPS9104.	1.6	0
58	A real-world study update: Efficacy and safety of anlotinib for advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21106-e21106.	1.6	0